U.S. health regulator extends review of Biogen's ALS drug
reuters.com
news
2022-10-17 11:42:13

Biogen logo and stock graph are seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration/File PhotoOct 17 (Reuters) - Biogen Inc (BIIB.O) said on Monday the U.S. Food and Drug Administration had extended the review of its experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) by three months.The company said the new target action date provided by the agency is April 25, 2023.Register now for FREE unlimited access to Reuters.comReporting by Bhanvi Satija in Bengaluru; Editing by Devika SyamnathOur Standards: The Thomson Reuters Trust Principles.
